

“PRINCIPLES OF CLINICAL PHARMACOLOGY” COURSE**2010-2011 SCHEDULE**

**All sessions will meet Thursday evenings from 6:30 p.m. to approximately 7:45 p.m.
in the NIH Clinical Center, Building 10, in the Lipsett Amphitheater in Bethesda, Maryland.
Course Web Site: <http://www.cc.nih.gov/training/training/principles.html>**

September 2nd	Introduction to course	J. Lertora (NIH CC)
<u>MODULE 1: PHARMACOKINETICS:</u>		
September 9th	Clinical pharmacokinetics	J. Lertora (NIH CC)
September 16th	Chemical assay of drugs and drug metabolites	S. Markey (NIH NIMH)
September 23th	Compartmental analysis of drug distribution	J. Lertora (NIH CC)
September 30th	Drug absorption and bioavailability	J. Lertora (NIH CC)
October 7th	Use of positron emission tomography (PET) in pharmacokinetics	R. Innis (NIH NIMH)
October 14th	Effects of renal disease on pharmacokinetics	J. Lertora (NIH CC)
October 21st	SPECIAL LECTURE: Pharmacokinetics in patients requiring renal replacement therapy	A. Atkinson (Northwestern Un.) and G. Susla (MedImmune, Inc.)
October 28th	Noncompartmental vs. compartmental approaches to PK analysis	P. Vicini (Pfizer, Inc.)
November 4th	Effects of liver disease on pharmacokinetics	J. Lertora (NIH CC)
November 18th	Population pharmacokinetics	R. Miller (Daiichi Sankyo, Inc.)
<u>MODULE 2: DRUG METABOLISM AND TRANSPORT:</u>		
December 2nd	Pathways of drug metabolism	S. Markey (NIH NIMH)
December 9th	Drug Interactions	S. Penzak (NIH CC)
December 16th	Pharmacogenomics	D. Flockhart (IUPUI)
January 6th	Biochemical mechanisms of drug toxicity	L. Pohl (NIH NHLBI)
January 13th	SPECIAL LECTURE: P-glycoprotein and drug transport	M. Gottesman (NIH OIR) and R. Innis (NIH NIMH)
January 20th	Equilibrative and concentrative drug transport	J. Ware (Genentech, Inc.)
<u>MODULE 3: ASSESSMENT OF DRUG EFFECTS:</u>		
January 27st	Dose response and concentration response analysis	J. Lertora (NIH CC)
February 3rd	Disease progression models and clinical trial simulation	D. Mould (Projections Research, Inc.)
February 10th	Physiological and laboratory markers of drug effect	J. Woodcock (FDA)
<u>MODULE 4: OPTIMIZING AND EVALUATING PATIENT THERAPY:</u>		
February 17th	Drug therapy in pregnant and nursing women	M. Fredericksen (Northwestern Un.)
February 24th	Drug therapy in the elderly	D. Abernethy (FDA)
March 3rd	Clinical analysis of adverse drug reactions	C. Chamberlain (NIH CC)
March 10th	Developmental and pediatric pharmacology	J. van den Anker (Children's National Medical Center)
March 17th	Quality assessment of drug therapy	C. Daniels (UCSD)
<u>MODULE 5: DRUG DISCOVERY AND DEVELOPMENT:</u>		
March 24th	Drug discovery	E. Sausville (Un. of Maryland Medical System)
March 31st	Pre-clinical drug development	C. Takimoto (Centocor R&D, Inc./Johnson & Johnson)
April 7th	Animal scale up and Phase I studies	R. Dedrick (NIH NIBIB) and J. Collins (NCI NIH)
April 14 th	Development of biotechnology products and large molecules	P. Garzone ((Pfizer, Inc.)
April 21th	Design of clinical drug development programs	C. Breder (FDA)
April 28th	Role of the FDA in guiding drug development	C. Peck (CDDS, UCSF)